Access Denied
Access Denied You don’t have permission to access ” on this server. Reference #18.5b071002.1770213679.2a82c4d2
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this year and face generic competition.
‘I’m worried about cash flow’: I’m 71 with a $2.7 million IRA and $470K in stocks. Why can’t I relax?
“My home is paid for and has an estimated value of $700,000.”
PepsiCo's drink sales are improving, and it's planning to cut snack prices
PepsiCo reported fourth-quarter earnings and revenue that topped Wall Street’s estimates.
Many U.S. households feel like they can’t get ahead financially — and they’re right
The top wealth holders outpace everyone else.
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Nvidia’s stock needs a spark. Here’s how it can generate one.
After a stretch of underperformance, Nvidia’s stock could come alive after earnings, upcoming industry events and the expected launch of new AI models by companies using its Blackwell chips.
Chipotle stock sinks as restaurant chain reports falling traffic, weak guidance
Chipotle stock has fallen about 33% over the last year, dragging the company’s market value down to about $51 billion.
Access Denied
Access Denied You don’t have permission to access ” on this server. Reference #18.2b221102.1770148814.3b0e2974
Novo Nordisk’s stock tumbles as drugmaker lays out case for declining sales in 2026
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
